Literature DB >> 7574541

Molecular mechanisms of antiviral resistance.

D W Kimberlin1, D M Coen, K K Biron, J I Cohen, R A Lamb, M McKinlay, E A Emini, R J Whitley.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7574541     DOI： 10.1016/0166-3542(95)00027-j

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  14 in total

1.  Synthesis of cyclopentanyl carbocyclic 5-fluorocytosine ((-)-5-fluorocarbodine) using a facially selective hydrogenation approach.

Authors:  Jong Hyun Cho; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  J Org Chem       Date:  2012-12-26       Impact factor: 4.354

2.  Sequence and transcriptional analysis of the guinea pig cytomegalovirus UL97 homolog.

Authors:  D S Fox; M R Schleiss
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

3.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

4.  Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir.

Authors:  J Bedard; S May; M Lis; L Tryphonas; J Drach; J Huffman; R Sidwell; L Chan; T Bowlin; R Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  Inhibitory activity and mechanism of silver nanoparticles against herpes simplex virus type 1.

Authors:  Xuanhe Pan; Yapeng Zhang; Yiming Zhao; Siqi Yao; Chaxiang Guan; Linqian Wang; Liyu Chen
Journal:  Arch Virol       Date:  2022-06-01       Impact factor: 2.685

6.  S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

Authors:  T Fujiwara; A Sato; M el-Farrash; S Miki; K Abe; Y Isaka; M Kodama; Y Wu; L B Chen; H Harada; H Sugimoto; M Hatanaka; Y Hinuma
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 7.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.

Authors:  F C Spector; L Liang; H Giordano; M Sivaraja; M G Peterson
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Anti-HSV activity of serpin antithrombin III.

Authors:  Debra C Quenelle; Tracy L Hartman; Robert W Buckheit; Mark N Prichard; Ralf Geiben Lynn
Journal:  Int Trends Immun       Date:  2014-04

10.  Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.

Authors:  J Duan; M Liuzzi; W Paris; M Lambert; C Lawetz; N Moss; J Jaramillo; J Gauthier; R Déziel; M G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.